Dallas, Texas (PRWEB) March 30, 2013
This report provides an overview of the global market for central nervous system (CNS) biomarkers, which are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, and predict treatment response. Analysis of global market trends, with data from 2010 through 2012, and projections of compound annual growth rates (CAGRs) through 2017. Also evaluates technologies such as genomics, proteomics, and imaging, and assessments of their advantages and disadvantages. The reports discusses CNS disease segments, prevalence, and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, and others. The report provides patent analysis. And comprehensive company profiles of major players.
Biomarkers are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, indicate what treatment options may be most effective in an individual patient’s case and predict treatment response. They play a role both in new drug R&D and in predicting the outcome of treatment in the medical setting. They are important tools for understanding disease mechanism, developing more effective treatments and improving the quality of patient care.
The report examines the role of CNS biomarkers in early discovery, in drug development and for future diagnostics. The global CNS biomarker market (http://www.reportsnreports.com/reports/70523-central-nervous-system-cns-biomarkers-technologies-and-global-.html) is discussed, and forecasts are made for this segment of the industry for the five-year period from 2012 to 2017. The technological segments of the market (genomics, proteomics and molecular diagnostics) are discussed by application, technology and geographic region. Individual disease segments are also discussed and describe gaps in treatment and limitations of current methods of diagnosis. The process of developing biomarkers from discovery to commercialization is described along with the forces in the industry that play an integral role, such as payers, providers and suppliers. Growth drivers and inhibitors that can affect CNS biomarker development and adoption are also discussed.
Study Goals and Objectives
Buy a copy of report @ http://www.reportsnreports.com/purchase.aspx?name=70523.
Scope of Report
Current and projected product forecasts during the forecast period of 2012 to 2017 are discussed. New product launches will be discussed. Revenue figures for 2011 are actual figures. Revenue figures for 2012 are actual figures except where actual results have not been reported, due to the timing of the release of the report.
The report includes an analysis of leading and emerging CNS biomarkers and related drugs for each CNS disorder. Profiles of producers of leading products and their specific products are provided. The report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products will alter the quality of life of patients receiving CNS biomarker diagnostics and treatment with associated drugs.
Market figures are based on revenues at the manufacturers’ level and are projected at a 2012-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, for new product introductions, expanded markets for existing products and other factors affecting the market.
Included in this report are forecasts by product, product category and by company from 2012 through 2017. The study is arranged to offer an overview of existing biomarker technology, drug markets for CNS diseases, drug and disease mechanism of action and companies, with forecasts broken down and covered by geographic region or country.
Patent and clinical trial information is reviewed for various candidate biomarkers. The status of approval by the FDA and regulatory agencies in other countries of biomarker diagnostics in each segment is reviewed.
Figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies.
All market share data presented is on a global basis, unless specifically noted.
Explore more reports on Biotechnology Market @ http://www.reportsnreports.com/market-research/biotechnology/.
ReportsnReports.com is an online market research reports library of 200,000+ reports and in-depth studies of 5000+ micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.
Read the full story at http://www.prweb.com/releases/central-nervous-system/cns-biomarkers-market/prweb10586394.htm.
Copyright©2012 Vocus, Inc.
All rights reserved